Please login to the form below
STING
This page shows the latest STING news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA and Mersana partner in potential $830m deal
Mersana’s proprietary Immunosynthen STING-agonist ADC platform generates systemically administered ADCs that locally activate STING signalling in both tumour-resident immune cells and antigen-expressing tumour cells, unlocking the ... This
Latest news
-
BioNTech and Ryvu partner to develop immuno-modulatory small molecule candidates
combinations. The STING pathway plays a critical role during infections and autoimmune disease, as well as one of the key innate immunity pathways responsible for antitumour immunity. ... The therapeutic targeting of STING is therefore seen as a
-
Bayer signs €250m pact with India’s Curadev for STING drugs
started working on STING drugs with potential in auto-immune and inflammatory diseases. ... Eli Lilly, for example, paid $12m upfront in a $620 million deal with Aduro Biotech at the end of 2018 for STING inhibitors, focusing on autoimmune diseases.
-
AbbVie cures STING fever with Mavupharma acquisition
Novartis paid $200m upfront for rights to Aduro’s STING programme in 2015. ... pipeline. Meanwhile, Mavupharma isn’t the only company trying to develop small-molecule STING agonists.
-
Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy
BMS’ interest was mainly on IFM’s STING and NLRP3 agonists and their potential in boosting immune responses to tumours.
-
New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake
salve its sting.
More from news
Approximately 2 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
Future-proofing pharma supply chains by improving inefficiencies in global health architecture
This will help to take the financial sting out of the price of preparation.
-
Cancer immunotherapy: What's on the horizon?
Among the plethora in the pipeline, Aurigene and BMS are looking at PD-1 inhibitors that can be dosed orally, Novartis, iTeos and Aduro are developing STING agonists that can
-
Live boulder, live louder
It’s like deconstructing a joke; by the end, the punchline loses its sting.
-
Medius Deal Watch table for March 2015
825. Aduro / Novartis. Licence and collaboration. Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway.
-
Pharma deals in March 2015
One such example is Novartis which has CAR-T and checkpoint inhibitor programmes and has now added Aduro's STING (Stimulator of Interferon Genes) technology as an additional string to its ... bow. Aduro has a number of preclinical small molecule cyclic
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
And the sting in the tail? The impact of COVID-19. Patients not presenting with symptoms, delays in diagnostics, delays in treatments…analysts suggesting that any progress being made on survival
-
A new prescription for the U.S. healthcare market?
patients over the next few decades may have a sting in the tail.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Sanofi's frexalimab shows promise in relapsing forms of MS
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Amgen reports positive results for Otezla in psoriatic arthritis
- Supply chain challenges in 2023
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
